Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics 2017 - Pipeline, Stakeholders, Deals, Industry Trends & Opportunities

This image opens in the lightbox

News provided by

Research and Markets

16 Nov, 2017, 21:30 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, November 16, 2017 /PRNewswire/ --

The "Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics" report has been added to Research and Markets' offering.

Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

mRNA is a rather versatile therapeutic modality and offers a range of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

It is increasingly recognized that oncolytic viruses not only are able to directly lyse cancer cells, but they also free" tumor specific neoantigens, indirectly acting as a cancer vaccine. The so far modest efficacy of oncolytic viruses still can be improved when combined with immune checkpoint inhibitors.

This lead to an increased partnering interest of the major immuno-oncology (I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens. Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo.

The original reports were published in January and June 2017, respectively:

  • The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
  • mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

Key Topics Covered:

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

1 Executive Summary

2 Introduction & Overview

3 Profiles of mRNA-based Vaccines & Therapeutics
3.1 Standardized Therapeutic Cancer mRNA Vaccines
3.2 Individualized Therapeutic Cancer mRNA Vaccines
3.3 Therapeutic Infectious Disease mRNA Vaccines
3.4 Prophylactic Infectious Disease mRNA Vaccines & Adjuvants
3.5 mRNA in Immuno-Oncology
3.6 mRNA Therapeutic for Monogenetic Diseases
3.7 mRNA Therapeutic for Other Diseases

4 Pipeline Analysis
4.1 Standardized mRNA Cancer Vaccines
4.2 Individualized mRNA Cancer Vaccines
4.3 Therapeutic mRNA Infectious Disease Vaccines
4.4 Prophylactic mRNA Infectious Disease Vaccines
4.5 Replicon RNA Infectious Disease Vaccines
4.6 mRNA Protein Therapeutics for Cancer and Cardiovascular Diseases
4.7 mRNA Protein Therapeutics for Ornithine TransCarbomylase (OTC) Deficiency
4.8 mRNA Protein Therapeutics for Cystic Fibrosis
4.9 mRNA Protein Therapeutics for Other Genetic Diseases
4.10 mRNA Antibody Therapeutics
4.11 Therapeutic mRNA-based Gene Editing
4.12 Ex vivo mRNA-based T-Cell Engineering

5 Profiles of Selected mRNA & Delivery Technologies
5.1 Ex vivo mRNA Loading
5.2 In vivo Carrier & mRNA
5.3 mRNA Vaccines & Stimulants / Adjuvants

6 Technology Analysis
6.1 mRNA Modifications
6.2 mRNA Efficiencies
6.3 Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines
6.4 Carriers for mRNA-based Protein & Antibody Therapeutics

7 Company Profiles
7.1 Companies focused on mRNA Therapeutics and Vaccines
7.2 Companies with a focus on self-amplifying mRNA (Replicon RNA)
7.3 Companies with a focus on mRNA Delivery
7.4 Companies with a focus on Gene Editing and CAR T-Cells
7.5 Companies focused on Contract Manufacturing of mRNA
7.6 Biopharmaceutical Companies with mRNA Programs
7.7 Major Pharmaceutical Companies with mRNA Programs

8 Stakeholder Analysis
8.1 mRNA Technology Companies
8.2 Pharmaceutical Companies with mRNA Programs

9 mRNA Manufacturing
9.1 In-house mRNA Manufacturing
9.2 Out-sourced mRNA Manufacturing

10 Financial Perspective on mRNA
10.1 mRNA Partnering Deals
10.2 Funded mRNA Programs

11 Outlook

12 References

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

1 Executive Summary

2 Introduction & Overview

3 Selection, Design & Construction of Oncolytic Viruses
3.1 Herpes Simplex Virus (HSV) - based Oncolytic Viruses
3.2 Adenoviruses - based Oncolytic Viruses
3.3 Vaccinia Virus - Based Oncolytic Viruses
3.4 Vesicular Stomatitis Virus - based Oncolytic Viruses
3.5 Newcastle Disease Virus - based Oncolytic Viruses
3.6 Various Oncolytic Viruses

4 Profiles of Oncolytic Viruses
4.1 HSV-based Oncolytic Viruses
4.2 Adenovirus-based Oncolytic Viruses
4.3 Vaccinia Virus-based Oncolytic Viruses
4.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
4.5 Newcastle Disease Virus-based Oncolytic Viruses
4.6 Various Oncolytic Viruses
4.7 Stem Cell-delivered Oncolytic Viruses

5 Analysis of Oncolytic Virus Pipeline
5.1 Overview of the Pipeline of Oncolytic Viruses
5.2 Approved and Marketed Oncolytic Viruses
5.3 Late Stage Development of Oncolytic Viruses
5.4 Combination of Oncolytic Viruses with Immune Checkpoint Inhibitors and Other Anti-Tumor Agents
5.5 Armed Oncolytic Viruses

6 Company Profiles
6.1 Pharma & Biotech
6.2 First Generation Oncolytic Virus Companies
6.3 Second Generation Oncolytic Virus Companies
6.4 Third Generation Oncolytic Virus Companies
6.5 Fourth Generation Oncolytic Virus Companies

7 Stakeholder Analysis
7.1 Pharma & Biotech
7.2 First Generation Oncolytic Virus Companies
7.3 Second Generation Oncolytic Virus Companies
7.4 Third Generation Oncolytic Virus Companies
7.5 Fourth Generation Oncolytic Virus Companies

8 Financing & Partnering
8.1 Grants, Credits & Donations
8.2 Venture Capital, Private Equity & Private Placements
8.3 Partnering Deals
8.4 Listing on the Stock Market
8.5 Mergers & Acquisitions

9 Trends & Opportunities

10 References

Companies Mentioned

mRNA Vaccines & Therapeutics 2017

  • Acuitas Therapeutics
  • Alexion Pharmaceuticals
  • Arbutus Biopharma
  • Arcturus Therapeutics
  • Argos Therapeutics
  • AstraZeneca
  • Bayer
  • BioNTech
  • Boehringer Ingelheim
  • CRISPR Therapeutics
  • CureVac
  • eTheRNA immunotherapies
  • Ethris
  • GlaxoSmithKline Vaccines
  • In-Cell-Art
  • Intellia Therapeutics
  • Janssen
  • Kernal Biologics
  • MaxCyte
  • Moderna Therapeutics
  • Novartis
  • PhaseRx
  • Precision NanoSystems
  • RaNa Therapeutics
  • Regeneron Pharmaceuticals
  • Roche
  • Sangamo Therapeutics
  • Sanofi
  • Siemens
  • Silence Therapeutics
  • Synthetic Genomics
  • Takeda Pharmaceutical Co
  • Tiba Biotechnology
  • TriLink BioTechnologies
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • ZIOPHARM Oncology

The Oncolytic Virus Landscape 2017

  • Amgen
  • Astellas Pharma
  • AstraZeneca (MedImmune)
  • Bayer
  • Benevir Biopharm
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Cold Genesys
  • DNAtrix
  • Daiichi Sankyo
  • Duke University start-up Company
  • GSK (GlaxoSmithKline)
  • GeneLux
  • Green Cross
  • Grifols
  • IGNITE Immunotherapy
  • Jiangsu Hengrui
  • Latima
  • Lee's Pharma
  • Lokon Pharma
  • Medigen Biotechnology
  • Merck
  • Multivir
  • Neotropix
  • Oncolys BioPharma
  • Oncolytics Biotech
  • Oncorus
  • Orca Therapeutics
  • Oryx
  • Otsuka Pharmaceutical Co
  • Pfizer
  • Profectus Biosciences
  • PsiOxus
  • Replimune
  • Roche
  • Shanghai Sunway Biotech
  • SillaJen
  • Sotio
  • StemImmune
  • StingInn
  • TILT Biotherapeutics
  • Takara Bio
  • Targovax
  • TheraBiologics
  • Theravir
  • Transgene
  • Turnstone Biologics
  • Unleash Immuno Oncolytics
  • VCN Biosciences
  • ViraTherapeutics
  • Viralytics
  • Virttu Biologics (TNK Therapeutics)
  • Vyriad
  • Wellstat Biologics
  • Western Oncolytics

For more information about this report visit https://www.researchandmarkets.com/research/5rjttv/report_package

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.